MedTrace Logo

Phase 4 Study - Mucinex D as Adjunct Therapy

NCT00441246 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2008-02-06

No results posted yet for this study

Summary

The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.

Conditions

  • Acute Respiratory Infection
  • Bronchitis
  • Rhinosinusitis

Interventions

DRUG

Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)

Sponsors & Collaborators

  • Adams Respiratory Therapeutics

    lead INDUSTRY

Principal Investigators

  • Helmut Albrecht, M.D. · Adams Respiratory Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-05-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441246 on ClinicalTrials.gov